Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Interleukin-12 antagonist activity of mouse interleukin-12 p40 homodimer in vitro and in vivo.

Gately MK, Carvajal DM, Connaughton SE, Gillessen S, Warrier RR, Kolinsky KD, Wilkinson VL, Dwyer CM, Higgins GF Jr, Podlaski FJ, Faherty DA, Familletti PC, Stern AS, Presky DH.

Ann N Y Acad Sci. 1996 Oct 31;795:1-12.

PMID:
8958912
2.

Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist.

Gillessen S, Carvajal D, Ling P, Podlaski FJ, Stremlo DL, Familletti PC, Gubler U, Presky DH, Stern AS, Gately MK.

Eur J Immunol. 1995 Jan;25(1):200-6.

PMID:
7843232
3.

Humanized antibody directed to the IL-2 receptor beta-chain prolongs primate cardiac allograft survival.

Tinubu SA, Hakimi J, Kondas JA, Bailon P, Familletti PC, Spence C, Crittenden MD, Parenteau GL, Dirbas FM, Tsudo M, et al.

J Immunol. 1994 Nov 1;153(9):4330-8.

PMID:
7930631
4.

Consensus repeat domains of E-selectin enhance ligand binding.

Li SH, Burns DK, Rumberger JM, Presky DH, Wilkinson VL, Anostario M Jr, Wolitzky BA, Norton CR, Familletti PC, Kim KJ, et al.

J Biol Chem. 1994 Feb 11;269(6):4431-7.

5.

Insight into E-selectin/ligand interaction from the crystal structure and mutagenesis of the lec/EGF domains.

Graves BJ, Crowther RL, Chandran C, Rumberger JM, Li S, Huang KS, Presky DH, Familletti PC, Wolitzky BA, Burns DK.

Nature. 1994 Feb 10;367(6463):532-8.

PMID:
7509040
6.

Endothelial monocyte-activating polypeptide II. A novel tumor-derived polypeptide that activates host-response mechanisms.

Kao J, Ryan J, Brett G, Chen J, Shen H, Fan YG, Godman G, Familletti PC, Wang F, Pan YC, et al.

J Biol Chem. 1992 Oct 5;267(28):20239-47.

7.

Cloning and expression of murine IL-12.

Schoenhaut DS, Chua AO, Wolitzky AG, Quinn PM, Dwyer CM, McComas W, Familletti PC, Gately MK, Gubler U.

J Immunol. 1992 Jun 1;148(11):3433-40.

PMID:
1350290
8.

Purification of recombinant human secretory phospholipase A2 (group II) produced in long-term immobilized cell culture.

Levin W, Daniel RF, Stoner CR, Stoller TJ, Wardwell-Swanson JA, Angelillo YM, Familletti PC, Crowl RM.

Protein Expr Purif. 1992 Feb;3(1):27-35.

PMID:
1422206
9.

Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys.

Hakimi J, Chizzonite R, Luke DR, Familletti PC, Bailon P, Kondas JA, Pilson RS, Lin P, Weber DV, Spence C, et al.

J Immunol. 1991 Aug 15;147(4):1352-9.

PMID:
1869828
10.

Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor).

Gately MK, Desai BB, Wolitzky AG, Quinn PM, Dwyer CM, Podlaski FJ, Familletti PC, Sinigaglia F, Chizonnite R, Gubler U, et al.

J Immunol. 1991 Aug 1;147(3):874-82.

PMID:
1713608
11.

Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor.

Gubler U, Chua AO, Schoenhaut DS, Dwyer CM, McComas W, Motyka R, Nabavi N, Wolitzky AG, Quinn PM, Familletti PC, et al.

Proc Natl Acad Sci U S A. 1991 May 15;88(10):4143-7.

12.

Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration.

Clauss M, Gerlach M, Gerlach H, Brett J, Wang F, Familletti PC, Pan YC, Olander JV, Connolly DT, Stern D.

J Exp Med. 1990 Dec 1;172(6):1535-45.

13.

Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells.

Stern AS, Podlaski FJ, Hulmes JD, Pan YC, Quinn PM, Wolitzky AG, Familletti PC, Stremlo DL, Truitt T, Chizzonite R, et al.

Proc Natl Acad Sci U S A. 1990 Sep;87(17):6808-12.

15.

A polypeptide factor produced by fibrosarcoma cells that induces endothelial tissue factor and enhances the procoagulant response to tumor necrosis factor/cachectin.

Clauss M, Murray JC, Vianna M, de Waal R, Thurston G, Nawroth P, Gerlach H, Bach R, Familletti PC, Stern D.

J Biol Chem. 1990 Apr 25;265(12):7078-83.

16.

Medium-scale ligand-affinity purification of two soluble forms of human interleukin-2 receptor.

Weber DV, Keeney RF, Familletti PC, Bailon P.

J Chromatogr. 1988 Sep 23;431(1):55-63.

PMID:
3266215
17.

Characterization of a factor(s) which synergizes with recombinant interleukin 2 in promoting allogeneic human cytolytic T-lymphocyte responses in vitro.

Wong HL, Wilson DE, Jenson JC, Familletti PC, Stremlo DL, Gately MK.

Cell Immunol. 1988 Jan;111(1):39-54.

PMID:
3276403
18.

Biochemical and functional analysis of soluble human interleukin-2 receptor produced in rodent cells. Solid-phase reconstitution of a receptor-ligand binding reaction.

Hakimi J, Seals C, Anderson LE, Podlaski FJ, Lin P, Danho W, Jenson JC, Perkins A, Donadio PE, Familletti PC, et al.

J Biol Chem. 1987 Dec 25;262(36):17336-41.

19.

Inhibition of spontaneous proliferation of human leukemic B cells from patients with chronic lymphocytic leukemia by anti-mu antibodies.

Steinberg J, Moore MA, Bona CA, Benjamin WR, Farrar JJ, Familletti PC, Platsoucas CD.

Clin Immunol Immunopathol. 1987 Sep;44(3):371-80.

PMID:
3113786
20.

Characterization of the phosphatidylinositol-glycan membrane anchor of human placental alkaline phosphatase.

Howard AD, Berger J, Gerber L, Familletti P, Udenfriend S.

Proc Natl Acad Sci U S A. 1987 Sep;84(17):6055-9.

21.

Structural characterization of human interferon gamma. Heterogeneity of the carboxyl terminus.

Pan YC, Stern AS, Familletti PC, Khan FR, Chizzonite R.

Eur J Biochem. 1987 Jul 1;166(1):145-9.

22.

Recombinant human interleukin 1 alpha: purification and biological characterization.

Gubler U, Chua AO, Stern AS, Hellmann CP, Vitek MP, DeChiara TM, Benjamin WR, Collier KJ, Dukovich M, Familletti PC, et al.

J Immunol. 1986 Apr 1;136(7):2492-7.

PMID:
3485152
23.

Production of human immune interferon from leukocytes cocultured with exogenous cells.

Familletti PC, Stremlo D.

Methods Enzymol. 1986;119:63-9. No abstract available.

PMID:
3020358
24.

Isolation of proteins from crude mixtures with silica and silica-based adsorbents.

Wolfe RA, Casey J, Familletti PC, Stein S.

J Chromatogr. 1984 Jul 27;296:277-84.

PMID:
6090487
25.

Molecular weight of the functional unit of human leukocyte, fibroblast, and immune interferons.

Pestka S, Kelder B, Familletti PC, Moschera JA, Crowl R, Kempner ES.

J Biol Chem. 1983 Aug 25;258(16):9706-9.

26.

In vitro synthesis of biologically active human leukocyte interferon directed by recombinant plasmid DNA.

Weissbach H, Goeddel DV, McCandliss R, Maeda S, Familletti PC, Redfield B, Staehelin T, Pestka S.

Arch Biochem Biophys. 1981 Aug;210(1):417-9. No abstract available.

PMID:
6170264
27.

Production of high levels of human leukocyte interferon from a continuous human myeloblast cell culture.

Familletti PC, McCandliss R, Pestka S.

Antimicrob Agents Chemother. 1981 Jul;20(1):5-9.

28.

Cell cultures producing human interferon.

Familletti PC, Pestka S.

Antimicrob Agents Chemother. 1981 Jul;20(1):1-4.

29.

Purification and molecular characterization of human fibroblast interferon.

Friesen HJ, Stein S, Evinger M, Familletti PC, Moschera J, Meienhofer J, Shively J, Pestka S.

Arch Biochem Biophys. 1981 Feb;206(2):432-50. No abstract available.

PMID:
6164342
30.

Convenient assay for interferons.

Rubinstein S, Familletti PC, Pestka S.

J Virol. 1981 Feb;37(2):755-8.

31.

Biological properties of natural and recombinant interferons.

Pestka S, Evinger M, Maeda S, Rehberg E, Familletti PC, Kelder B.

Tex Rep Biol Med. 1981-1982;41:31-6. No abstract available.

PMID:
6184819
32.

Induction, production, and concentration of interferon produced by a myeloblast culture.

Familletti PC, Costello L, Rose CA, Pestka S.

Methods Enzymol. 1981;78(Pt A):83-6. No abstract available.

PMID:
6173651
33.

Induction and production of human interferon with human leukemic cells.

Hershberg RD, Gusciora EG, Familletti PC, Rubinstein S, Rose CA, Pestka S.

Methods Enzymol. 1981;78(Pt A):45-8. No abstract available.

PMID:
6173628
34.

Induction and production of interferon with human leukocytes from normal donors with the use of Newcastle disease virus.

Waldman AA, Miller RS, Familletti PC, Rubinstein S, Pestka S.

Methods Enzymol. 1981;78(Pt A):39-44. No abstract available.

PMID:
6173618
35.

A convenient and rapid cytopathic effect inhibition assay for interferon.

Familletti PC, Rubinstein S, Pestka S.

Methods Enzymol. 1981;78(Pt A):387-94. No abstract available.

PMID:
6173617
36.

Use of commercial sources of Newcastle disease virus: production, purification, and characterization.

Familletti PC.

Methods Enzymol. 1981;78(Pt A):305-9. No abstract available.

PMID:
6173608
37.

Construction and identification of bacterial plasmids containing nucleotide sequence for human leukocyte interferon.

Maeda S, McCandliss R, Gross M, Sloma A, Familletti PC, Tabor JM, Evinger M, Levy WP, Pestka S.

Proc Natl Acad Sci U S A. 1980 Dec;77(12):7010-3.

38.

Human leukocyte interferon produced by E. coli is biologically active.

Goeddel DV, Yelverton E, Ullrich A, Heyneker HL, Miozzari G, Holmes W, Seeburg PH, Dull T, May L, Stebbing N, Crea R, Maeda S, McCandliss R, Sloma A, Tabor JM, Gross M, Familletti PC, Pestka S.

Nature. 1980 Oct 2;287(5781):411-6.

PMID:
6159538
39.

Human leukocyte interferon: production, purification to homogeneity, and initial characterization.

Rubinstein M, Rubinstein S, Familletti PC, Miller RS, Waldman AA, Pestka S.

Proc Natl Acad Sci U S A. 1979 Feb;76(2):640-4.

40.

Synthesis and processing of the mouse MOPC-321 kappa chain in Xenopus laevis oocytes.

Jilka RL, Familletti P, Pestka S.

Arch Biochem Biophys. 1979 Jan;192(1):290-5. No abstract available.

PMID:
107859
41.

Human leukocyte interferon purified to homogeneity.

Rubinstein M, Rubinstein S, Familletti PC, Gross MS, Miller RS, Waldman AA, Pestka S.

Science. 1978 Dec 22;202(4374):1289-90.

PMID:
725605

Supplemental Content

Loading ...
Support Center